Earlier this week, Merck entered into an agreement to acquire Tilos Therapeutics for up to $773 million. Such acquisitions demonstrate how heavily invested Merck is in immuno-oncology, an area in which it is currently well-positioned with the PD-1 inhibitor Keytruda.
Merck’s Full Court Press On Oncology
